Bentley Pharmaceuticals, Inc. announced has extended its R&D collaborative agreement with Pfizer Inc. Under the terms of the agreement, Bentley and Pfizer will continue to evaluate certain Pfizer compounds for enhanced delivery.
As part of the agreement, Pfizer has access to Bentley’s drug delivery platform through a research license.
Pfizer will continue to provide the funding necessary to enhance its compounds in formulations that include Bentley’s patented drug-delivery technology.
Commenting on the collaboration, James R. Murphy, Chairman and CEO of Bentley, said, “We are pleased to expand our collaboration with Pfizer, which is known for its commitment to and strong investment in R&D. We are confident that Bentley’s technology will continue to demonstrate impressive enhancement that improves absorption and utilization of proprietary drugs.” Murphy continued, “We look forward to providing Pfizer continued access to our proprietary drug delivery technology, recognizing that Pfizer is among the world’s leading pharmaceutical companies.”
Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products.
Bentley’s proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes.